Long-acting β 2-agonists (LABAs) have been shown to be effective first-line bronchodilators
in the treatment of COPD patients, and inhaled corticosteroids (ICSs) have been shown to …

Since chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
obstruction, inhaled bronchodilators form the mainstay of treatment. A variety of new inhaled …

Background To assess the symptomatic and cost burden among patients initiating long-
acting bronchodilator (LABD) therapy and impact of adherence on healthcare resource use …

Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory
disease and its prevalence is increasing worldwide, in both industrialised and developing …

Long-acting bronchodilators in combination with inhaled corticosteroids (ICS) are
recommended to decrease the risk of recurrent exacerbations in patients with Global …

A volume of published evidence sustains the role of long-acting β2-agonists in the treatment
of stable COPD. 1–5 These agents not only induce prolonged bronchodilation, but also …

Purpose There is a high prevalence of chronic obstructive pulmonary disease (COPD) in the
United States (US). Although guidelines are available for the treatment of COPD, evidence …

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
globally, and its prevalence is projected to continue to increase owing to trends in smoking …

Objectives To investigate the determinants of patient withdrawal from our study, and the
effect of these withdrawals on the outcome of treatment with inhaled corticosteroids in …

Chronic obstructive pulmonary disease (COPD) is a treatable disease characterized by
progressive airflow limitation. Prevention of disease progression, improvement of symptoms …